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Protein engineering is a valuable tool that allows scientist to explore how an
enzyme works by mutation of key residues. This method has been used to improve
function or stability of enzymes, thus allowing their use in both the lab and in
industry to be expanded. Genetic incorporation of unnatural amino acids (unAA)
can be used with protein engineering to exceed the current limitations, due to the
limited number of functional groups of the 20 common amino acids.
The majority of this thesis will discuss the progress on incorporating the
various unAA into the active site of the enzyme, Dehydroquinate Synthase (DHQS).
Previously this enzyme has been understood through the use of inhibitors as well as
crystallization of the enzyme with its substrate and cofactors. This work begins to
explore the chemical reactions of this enzyme catalysis, as well as enhancing the
known tools of genetic incorporation of unAA. This masters thesis focuses on my
work the in: (1) the synthesis of the unAAs including hydroxyquinolin-alanine and
2-(5-carboxythienyl)alanine; (2) the identification of aminoacyl tRNA synthetase
recognizing 2-(5-bromothienyl)alanine, 2-mercapto-L-histine, diiodo-histine, and 2-

(5-carboxythienyl)alanine; and (3) the incorporation of hydroxyquinolin-alanine
and 2-(5-bromothienyl)alanine into DHQS and the evaluation of the resulting
mutants.
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CHAPTER 1
BACKGROUND

1.1 Introduction
In nature there are 20 common amino acids that are ordered and then folded in
endless combinations to create enzymes that catalyze almost all chemical reactions
in biological system. These enzymes sometimes are able to catalyze the synthesis of
molecules through amazing and difficult chemistry. As enzymes are found in nature
and often can catalyze thermodynamically or entropically unfavorable reactions at
room temperature, exploration and manipulation of enzymes has great potential to
efficiently produce chemicals needed for our economy today with a greener
footprint.
Protein engineering has been used as a tool to generate enzyme with improved
properties, such as increased catalytic activity or improved thermo stability.
Traditionally protein engineering had only the twenty common amino acids to use
with their limited number of functionality of their side chains. An intuitive question
is if proteins functions can be improved by introducing novel amino acids with
unique physical, chemical, or biological properties. To answer this question, genetic
incorporate unnatural amino acids (unAAs) in response to amber nonsense codon
has been developed by modifying a cell’s translational machinery.

With a

combination of tradition protein engineering and genetic incorporation of unAAs
the method to study a protein’s structure and function could be enhanced.
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The potential to change an enzyme by the cell’s own machinery was first hinted
at in 1962 by two papers demonstrating that it is the tRNA not the amino acid itself
that dictates the protein code.1,2 These papers showed that alanine could be
incorporated into a peptide chain by the translational machinery after chemically
converting a Cys-tRNACys into Ala-tRNACys that the alanine could still be
incorporated into a peptide chain by the translational macheniery.1,2 This in vitro
mis-acylation was expanded by showing multiple types of amino acids could be
synthetically charged,
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then incorporated.

The Johnson group showed

incorporation of an unAA in 1994, showing the incorporation of a fluorescently
labeled lysine at a lysine codon.4
In 1989 the Schultz group developed a general approach for the site-specific
incorporation of unnatural amino acids directly into proteins in response to amber
nonsense codon in vivo. 5 This method prevented unspecific incorporation of
canonical amino acids, as the method involved first changing a specific codon in a
target gene into an amber TAG codon through site directed mutagenesis. The
following mRNA would be translated entirely by an amber suppressing tRNA that is
chemically aminoacylated with an unAA of interest (Figure 1-1); thus allowing for a
full-length protein with a site-specific incorporation of the unnatural amino acid.5
Though many types of unAA could be incorporated there were limitation due to low
yields of the acylated tRNA. As such this incorporation method is only particularly
useful in situations that microinjections can be used, as shown with Xenopus oocytes
in the 1995 paper by the Dougherty and Schultz group. 6
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Figure 1-1: Generalized method of site-specific incorporation of unAAs.
As in vitro design of incorporating unAA has limitations in how much tRNA can
be charged the Schultz group proposed, and demonstrated in 2001, incorporation of
a free unAA using a cell’s machinery.7 Incorporation of an O-methyl-L-tyrosine was
successfully done by use of the Methanococcus jannashii (Mj) tyrosyltRNATyr/TyrRS
pair. 7 This archaebacterium tRNATyr is different from the E. coli tRNATyr so after
further modifying of MjtRNA and transfer it into an E. coli host there was little
recognition by the host’s endogenous tRNA synthetases.7 Furthermore the MjTyrRS
was mutated for increased specificity of the unAA over naturally occurring
tyrosine.7
Since this method was first published it has been expanded and improved many
times.8 With over 150 unnatural amino acids (unAAs) reported to be successfully
incorporated into proteins, the potential for adding new chemistry to enzymes and
creating artificial enzymes has becomes a process of engineering and rationally
design.8,9,10 The ability to incorporate multiple and various unAAs has also
expanded since 1989, as now beyond the amber nonsense codon, the low-abundant
AGG codon,11,12 the tRNAPyl

recognizing CUA codon, 13,14 and the quadruplet
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codon,15 all have been shown to successfully incorporate unAAs site specifically into
proteins.

1.2 Dehydroquinate synthase
The goal of my research is to apply unAA mutagenesis approach to the
engineering of dehydroquinate synthase (DHQS.)
The

7-phospho-3-deoxy-D-arabino-heptulosonate

phosphate

lyase,

or

dehydroquinate synthase (DHQS) is a sugar phosphate cyclase with a very
interesting mechanism. It is found in nature as one of seven enzymes that make up
the

shikimate

pathway,

transforming

D-erythrose

4-phosphate

and

phosphoenolpyruvate to chorismate, the pathway is shown in Figure 1-2. 16
Byproducts and chorismate are used as metabolites in a verity of pathways to form
phenylalanine, tyrosine, and tryptophan; essential amino acids to higher order
organisms; as well as other aromatic compounds like vitamin E and K, folic acid,
ubiquinone, and naturally found coumarins.16

16

Figure 1-2: Shikimate pathway adapted from Reviews of Herrman17 and Haslam. 16
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The enzyme DHQS is particularly interesting and the focus of this work as the
enzyme transforms deoxy-D–arabino-heptulosonate 7-phostphate (DAHP) into 3dehyroquinate (DHQ) through a series of five reactions. The enzyme catalyzes an
alcohol oxidation, phosphate β-elimination, carbonyl reduction, a ring opening, and
finally an intramolecular aldol condensation.17,18 As there are multiple steps
catalyzed by DHQS there was a proposed mechanism for the transformation of
DAHP to DHQS with a verity of proposals to the steps the substrate went through.
The Brown group proposed mechanism of DHQS shown in Figure 1-3 with
convincing evidence of the crystallization of DHQS with the cofactors and substrates
in 1998, demonstrating how the residues interacted with the substrate in the
transformation of DAHP into DHQ.18
The DHQS, encoded by the aroB gene, is assisted with its multiple reactions
with help of the two cofactors, NAD and a divalent metal (either Co2+ or Zn2+).18 The
metal ion is dependent of the origin of the DHQS, as from overexpressed E. coli
DHQS was found to have tightly bound Co2+ to have highest activity, while addition
of Zn2+ has been shown to restore most activity.19 While the DHQS from the AROM
protein of Aspergillus nidulans, which was used by the Brown group for
crystallization bound Zn2+ preferentially.18 The NAD+ and the divalent metal act in
the first enzymatic step of DHQS oxidizing the C5 alcohol as shown in Figure 1-3.17,18
The divalent metal ion likely facilitates a hydride transfer from C5 to NAD+ and a
proton loss of the C5 hydroxyl.18 Though the crystallization and most recent
mechanism proposal is from the DHQS from Aspergillus nidulans, the E. coli DHQS is
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comparable in structure and activity and as such all mutants in this work are
mutated based on the crystal structure of Aspergillus nidulans DHQS (Figure 1-4). 18

Figure 1-3: The mechanism for DHQS of Aspergillus nidulans. 18

Figure 1-4: Crystal structure of Aspergillus nidulans DHQS active site. 18
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The complex and multistep enzyme mechanism of the DHQS makes this
enzyme an interesting candidate for investigation, manipulation and introducing
new chemical potential by incorporation of unAAs at key active site residues. As
there are so many different reactions catalyzed by this enzyme there are a lot of
potential to influence the chemistry of the enzyme by what amino acid is
incorporated at key residues. Furthermore as this enzyme is a metalloenzyme, so
the potential to influence the chemistry through the chelating residues is also an
interesting area to explore. This enzyme mechanism was described by Bartlett in a
1988 paper, “The mechanistic details of the transformation reflect both clever
functional group manipulation and stereochemical dexterity on the part of the
enzyme.”20 The general mechanism is solved now the interesting part is exploring
the chemistry behind it.

1.3 Experimental Design
The way this work explores the chemistry of the DHQS mechanism is through
incorporation of unAAs site specifically in place of key active-site residues. The
selection for aminoacyl-tRNA synthetase (aaRS) to charge a tRNA for incorporation
of a unAA was done using a similar method to the unAA selection method used by
the Schultz group at The Scripps Research Institute, and the experimental design is
described below (aminoacyl-tRNA synthetaseUAA Selection) and is used in the
selection process of this work. To check the efficiency and relative activity of the
DHQS mutants, the DHQS gene was inserted downstream of an inducible promoter
on a plasmid. These plasmids were then transformed into DHQS knockout hosts to
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monitor functionality of mutants (DHQS Mutant Activity Screening). Both methods
are described in this section.

Aminoacyl-tRNA Synthetase (aaRS) Selection
The unAA for our interest to incorporate are histidine derivatives, such as 2-(5bromothienyl)alanine,

2-mercapto-L-histine,

carboxythienyl)alanine (Figure 1-5).

diiodo-histine,

and

2-(5-

In order to genetically incorporate these

histidine analogs, we chose to evolve a tRNAPyl-pyrrolysyl-tRNA synthetase (PylRS)
pair from a Methanosarcina barkeri PylRS library.

Previous work has shown

successful incorporation of a few unAA with structures similar to histidine using a
tRNAPyl-PylRS variant derived from M. barkeri.21,22 The tRNAPyl-PylRS pair is
responsible for the genetic incorporation of pyrrolysine (the 22nd amino acid) into
protein, recognizing the Amber nonsense codon.
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Figure 1-5: 2-(5-bromothienyl)alanine (1), 2-mercapto-L-histine (2), diiodo-histine
(3), and 2-(5-carboxythienyl)alanine (4)
The basic outline of selection of PylRS/tRNAPyl pairs is adopted from an
established method by the Schultz lab for the Methanosarcina barkeri (Mb) PylRS
3N library (Figure 1-6A and B). The randomized sites in the 3N MbPylRS library are
L270, Y271, L274, C313, and V401. Each amino acid is randomized by the expressed
sequence at the codon position, the codons are randomized by NNK degenerative
oligonucleotides (N=A,T,G,C and K=G,T).

The randomized sequences are then

cloned into the pBK plasmid under control of a constitutive glnS promoter with a
kanamycin resistance marker (Kanr) for plasmid maintenance.
To remove most synthetase mutants that would charge canonical amino
acids this plasmid was co-transformed with a negative selection plasmid, pNEG-PylT
(Figure 1-6A). This plasmid harbors a ribonuclease barnase gene with two amber
nonsense codons at permissive sites. This plasmid also has a copy of tRNAPyl under

22
a Ipp promoter. When grown without the target unAA any synthetase variants that
could charge canonical amino acids would produce full length barnase. As barnase
is cytoxic, cells containing these synthetase variants would die, and thus enrich the
library with synthetase variants that would be selective against canonical amino
acids.

These plasmids were harvested and co-transformed with the positive

selection plasmid.

23

Figure 1-6A: Negative selection outline for unAA against PylRS library

24

Figure 1-6B: Positive selection outline for unAA against PylRS library
The positive selection plasmid (pRep) has one copy of the MbtRNAPyl and a
chloramphenicol resistance marker (Cmr) with a TAG codon at a permissive site.
This plasmid also contained a T7 RNA polymerase gene with a TAG codon at a
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permissive site to act as a second reporter (Figure 1-6B). The cells are grown on
various low levels of chloramphenicol concentration with the unAA at 1mM-2mM
concentrations.

Efficient charging of the amber suppressor tRNAPyl by PylRS

variants with the unAA results in cells that are chloramphenicol resistant and
fluorescent. Both growth and fluorescence should indicate a synthetase with high
activity to charge an amino acid to the tRNA. Cells harboring PylRS variants capable
of utilizing the desired unAA but not endogenous amino acids will survive both
negative and positive selections.
Colonies with high relative fluorescence were selected for replication plates
with and without the unAA of interest. The colonies that were able to grow and
exhibit fluorescence only on the plates with unAA were selected for further
characterization. The logic behind this being that only the Mb-PylRS that are able to
charge the unAA at high efficiency would be able to show strong fluorescence and
chloramphenicol resistance. To ensure the hit was not a false positive the MbPylRSUAA was transformed into a strain with pLei-GFPUV, this GFP gene has an amber
codon at a permissive site (Asn149). When induced with the unAA and induced
without the UAA, if the Mb-PylRSUAA is actually selective then the relative fluorescent
signal of the induced culture and unAA will be folds higher. This general method
was used consistently in the work following.

DHQS Mutant Activity Screening
To efficiently check the relative activity of the mutant DHQS enzymes, plasmids
containing the aroB gene with amber mutations of the interest were transformed
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into strains with decreased activity of aroB or strains with aroB being fully knocked
out. By growing these strains with the mutant DHQS in cultures without aromatic
amino acids and vitamins the cells can only grow if the DHQS is functional. This
method is useful as it quickly gives a relation to the activity of the mutant enzyme in
comparison to the wild type enzyme.
The strains used in this work were the JWΔaroB and the AB2847 strain. Both
were ordered and received from the E. coli Genetic Stock Center at Yale University
(Section 4.7). The JW strain, originally JW3352-1, is a knockout with the aroB gene
removed and a kanamycin marker as a placeholder. The marker was removed
(Section 4.7 (3) ) and was used as a host for the DHQS mutants. The other strain,
AB2847, is an older strain that was first reported in 1966 with a full aroB gene.
There are two mutations compared to the wild-type aroB sequence at position 93,
HisCAT mutated to GlnCAG, and position 254, GluGAA mutated to LysAAA.23 This strain
was reported to produce the DHQS with a reduced specific activity of 0.025
compared to the DHQSwt (specific activity, 1.16).23 Either of these strains were
important to in this work not only because it provided an easy method to compare
efficiency of the DHQS mutants but also it reduced the background of wild type
DHQS protein found in the cell.

1.4 Conclusion
As the DHQS is both a metalloenzyme and can catalyze a variety of reactions as
described in section 1.2 it creates a very interesting model for unnatural amino acid
incorporation. The diversity of reactions creates a platform to test how various
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unAA could affect the reactivity of an enzyme. Optimization of DHQS is unlikely to
result in any major impact to how aromatic amino acids are synthesized and
isolated for commercial use. However the potential to explore what factor effects
the activity of the enzyme by use of amino acid analogues would not only be
interesting in the interest of science, but also in terms of a bigger picture a way to
rationally design an inhibitor of DHQS. Inhibitor of DHQS is important as this
pathway is not found in higher order eukaryotes but is found in apicomplexan
parasites such as malaria.24 Information in how this enzyme works could lead to
better development of anti-microbial and anti-parasitic compounds.

Chapter 2
Metal Chelating Sites in DHQS

2.1 Introduction
The first sites targeted for the possible incorporation of unAA were the two
metal chelating sites in the DHQS. The glutamic acid (E) 184 and histidine (H) 264
sites in E. coli DHQS acts to bind cobalt (II) (Co2+) in the active site. 18 The carboxylic
acid side chain of the glutamic acid and the imidazole ring of the histidine act as
electron donors, binding the Co2+, where it is used by the enzyme to oxidize the C5
alcohol in the first step of the mechanism.19, 19 As the Aspergillus nidulans uses Zn2+
as the metal to oxidize the alcohol, there is potential to change the activity of the
E.coli DHQS by changing what is metal ion is chelated in the active site and how
tightly the metal is bound. The unAA used in this project was hydroxyquinolin-
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alanine (HQAla) as shown in Figure 2-1. This unAA has been shown to have strong
binding to divalent metals, particularly Cu2+.25 HQAla as a strong metal chelator
could have the potential to change the relative activity of the E. coli DHQS.

Scheme 2-1: Synthetic scheme of hydroxyquinolin-alanine.26

Scheme 2-2: Biosynthesis of hydroxyquinolin-alanine.25
The unAA, HQAla, was initially synthesized by the Fridkin group (Figure 2-1) at
the Weizmann Institute of Science in hopes of treating Alzheimer Disorder; using its
nature as a chelating agent, it assisted a radical scavenger to pass the blood brain
barrier successfully.26 Then a biosynthesis of this unAA was developed by the Wang
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group in the Institute of Biophysics, Chinese Academy of Sciences. This biosynthesis
started with the precursor of 8-hydroxyquinoline and via a double mutated tyrosine
phenol lyase (TPL) transformed it into the unAA HQAla at an overall yield of 40%
(Figure 2-2).25 We followed the organic synthesis route to obtain HQAla at gram
scale quantities. Though we referenced the Fridkin paper to synthesize HQAla, the
synthesis was optimized as described in section 4.2 to get higher yields in
intermediate steps.

2.2 Mutation of Metal Chelating Sites at E184 and H264
The sites targeted for incorporation in the DHQS of the unAA, HQAla, were
the E184 and H264 sites. These sites were selected as the crystal structure of A.
nidulans DHQS showed these residues chelate to the divalent metal ion.18 The DHQS
from A. nidulans is analogous to the E. coli DHQS, as such the sequence of both DHQS
can be compared. The same residues can be targeted for the E. coli for mutation,
though the residues come at different points in the sequence. To ensure that these
two residues are responsible for the binding of the divalent metal, we conducted an
alanine scan of the two residues.
The alanine scan was achieved by mutating each of the two residues to
alanine through site directed mutagenesis (SDM). As a result, the proposed metal
chelating side chains of E184 and H264 would be removed and replaced by a nonreactive methyl group. The relative activity of these alanine DHQS mutants could be
monitored by the growth rate of these mutant sequences in the JWΔaroB strain in
the presence of these mutants.
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After amplifying out the aroB gene from Δ3 E.coli plasmid pQZ1.022, the aroB
gene was cloned into the pBK vector (pBK-aroBwt). Three DHQS mutants were
constructed including, the DHQSE184A (encoded in plasmid pBK-aroBE184A),
DHQSH264A

(encoded

in

plasmid

pBK-aroBH264A),

and

a

double

mutant

DHQSE184A/H264A (encoded in plasmid pBK-aroBE184A/H264A) (Section 4.6). After
transforming these mutants into the JWΔaroB strain, they were cultivated under
two different conditions: (1) M9 minimal media with aromatic amino acids and
vitamins (Figure 2-1), and (2) M9 minimal media without aromatic amino acids and
vitamins (Figure 2-2). The OD of each culture was monitored over 48 hours. The
original plasmid pQZ1.022 was used as a negative control as there is no promoter
for the expression of the DHQS, so no activity was expected to assist in the growth of
the cells. The plasmid, pBK-aroBwt, was used as a positive control.
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Mutant in JWΔaroB host grown in M9 minimal media
with aromatic amino acids and vitamins
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Figure 2-1: Growth JWΔaroB/pBK-aroB variants at 37°C in M9 Minimal Media with
aromatic amino acids and vitamins.
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Mutant in JWΔaroB host grown in M9 minimal media
without aromatic amino acids and vitamins
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Figure 2-2: Growth of JWΔaroB/pBK-aroB varients at 37°C in M9 Minimal Media
without aromatic amino acids and vitamins.
Over the incubation period cultures with aromatic amino acids and vitamins
grew at a very similar rate to about the same relative OD, as the functionality of the
DHQS mutants expressed does not matter for the growth of the strain. The data
shown in Figure 2-1 shows the standard growth potential of the JWΔaroB of each
culture.

The cultures without the aromatic amino acids and vitamins added

however rely on the activity of the DHQS mutants. In the case of the DHQSwt the
enzyme was active and the cells were able to reach a similar OD in 24 hours as the
cultures with aromatic amino acids and vitamins.
The DHQS variants with alanine mutations did not retain the same activity as
the DHQSwt. The single Glu184Ala mutant retained some activity as after 48 hours
the cells reached a similar OD to the positive control culture. The single His264Ala

33
mutant did not retain activity. A similar result of non-activity was shown of the
double mutant containing Glu184Ala and His264Ala.

Comparing each of the

mutants, DHQSE184A, DHQSH264A, and DHQSG84A/H264A, shows that the His264 position
probably has more effect in the chelation of the Co2+. This is likely due to the ability
of not only the nitrogen but also the pi electrons of the imidazole ring that assists in
chelation of the metal. Overall the double mutation shows that the DHQS no longer
retains any of its activity if these metal chelating sites are removed.
The alanine mutant, pBK-aroBE184A/H264A, was then used as the template for
another round of SDM to introduce amber nonsense codon. Again three mutants
were constructed: DHQSE184TAG/H264A, DHQSE184A/H264TAG, and DHQSE184TAG/H264TAG.
These aroB genes were sub-cloned to a pJF vector, forming the plasmids pJFaroBE184TAG/H264A, pJF-aroBE184A/H264TAG, and pJF-aroBE184TAG/H264TAG (Section4.6).
This construct contains a regulative lac promoter, allowing us to turn on and off the
expression of the gene with more control than with the pBK vector. These mutants
were co-transformed with the synthetase Mj-HqAlaRS encoded on the pEvol plasmid
as designed and selected by the Wang group.25 This aaRS was selected from a M.
jannaschii TyrRS library and had the following mutations from the wild-type
MjTyrRS: Tyr32His, Ile63Val, Leu65His, His70Gly, Phe108Arg, Tyr109Val,
Asp158Asn, Leu162Asp, Cal164Gly.25 This plasmid construct was received from the
Wang lab and independently we verified the incorporation efficacy with a cotransformed sfGFPTAG66 mutant (Fig 2-3). To ensure a high enough intracellular
concentration of HQAla, we used a final concentration of 2mM of HQAla in culture
media. Then to induce these cultures, we used 0.5mM of IPTG and 0.2% arabinose.
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Emission and Excitation of sfGFP-66HQAla
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Figure 2-3: Excitation and emission spectra of sfGFP-HQAla66. The replacement of
Tyr66 with HQAla66 results in a red-shifted emission maximum of sfGFP-HQAla66
(545 nm) from sfGFPwt (515 nm).25

2.3 Growth Test of Mutants DHQSE184TAG/H264A and DHQSE184A/H264TAG
The experimental design, by use of the JWΔaroB as a host to express DHQS
variants, allows us to effectively test the activity of the mutant enzymes without the
need to isolate each enzyme. The mutants DHQSA184TAG/H264A and DHQSE184A/A264TAG
transformed in the JWΔaroB strain were inoculated into five different cultures (M9
minimal media) and grown over 48 hours at 37°C. These five cultures included a
positive control (an induced culture with aromatic amino acids and vitamins added)
and two negative controls (one culture non-induced and the other culture induced,
both without aromatic amino acids and vitamins). The two experimental cultures
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that were induced with IPTG and 2mM of HQAla without aromatic amino acids and
vitamins; though one culture trace elements were added to promote better cells
growth. All cultures were inoculated with 100 μL of washed cells (Section 4.6 (3))
and OD was measured at inoculation, 16 hours, 24 hours, and 48 hours (Fig 2-4 A
and B).

Growth test of DHQSE184TAG/H264A in
JWΔaroB with HQAla
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Figure 2-4A: Growth of JWΔaroB/ pJF-aroBE184TAG/H264A at 37°C in M9 Minimal
Media without aromatic amino acids and vitamins unless noted.
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Growth test of DHQSE184A/H264TAG in
JWΔaroB with HQAla
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Figure 2-4B: Growth of JWΔaroB/ pJF-aroBE184A/H264TAG at 37°C in M9 Minimal
Media without aromatic amino acids and vitamins unless noted.
However, as observed, even after 48 hours, there was little growth of either
the DHQSE184TAG/H264A or the DHQSE184A/H264TAG mutant in the absence of aromatic
amino acids and vitamins. This meant that there was no activity of the DHQS
mutants. To ensure that the issue did not lie in the incorporation efficiency of HQAla
into the enzyme, the DHQSE184TAG/H264A and DHQSE184A/H264TAG mutants were
expressed in JWΔaroB in rich LB cultures in the presence of the pEvol plasmid and 2
mM HQAla. The cell lysate was partially purified by affinity chromatography. The
protein samples were subsequently analyzed with Western Blot using anti-His
antibody as the DHQS mutants are modified with a C-terminal histidine tag to assist
in purification (Fig 2-5).
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Figure 2-5: Western Blot of DHQSE184TAG/H264A and DHQSE184A/H264TAG mutants, non induced,
induced (0.5 mM IPTG and 0.02% arabinose),, induced with HQAla (2mM HQAla, 0.5 mM
IPTG and 0.02% arabinose), and induced with Tyrosine (2mM Tyrosine, 0.5 mM IPTG and
0.02% arabinose), in M9 media with aromatic amino acids and vitamins. Full length DHQS is
39kDa.

As Figure 2-5 shows, there was protein produced in the induced cultures
with the 2mM of HQAla. However, it is important to note that there is significant
background in the induced culture without HQAla, indicating there was
incorporation of a canonical amino acid. Checking the incorporation efficiency of
the HQAla in the M9 minimal media without aromatic amino acids and vitamins is
difficult as there is so little cells in the solution. Attempts at doing a Western Blot of
these cultures were too faint to make any key distinctions of DHQS expressed.
The background of unspecific amino acid incorporation in Figure 2-5 was
expected, as there is some background in most unAA incorporation and usually
other mutations are necessary to increase specificity. 27 The aminoacyl-tRNA
synthetase that was mutated to incorporate HQAla is derived from a library
developed from tyrosine tRNA synthetase,25 so it is likely in these rich culture
tyrosine is being incorporated due to the nature of the synthetase. However it is not
clear why there is high selectivity of the HQAla in the selection experiments, but in
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this case there is likely little protein with the incorporated HQAla. One possible
reasoning is that there is overcrowding in the active site. As the HQAla is a bicyclical
structure, as it is considerably more bulky than either the glutamic acid or histidine.
The histidine 264 might have less of an issue in the incorporation of HQAla as it had
a bigger footprint, however in both situations incorporation may result in misfolding and/or truncated proteins
From the Western, shown in Figure 2-5, it is likely that tyrosine is being
incorporated at the amber nonsense codon. Significantly more protein is expressed
in the DHQSE184A/H264TAG, and after incubation in M9 minimal media over 72 hours, a
slight increase in growth were observed by these cultures. These factors then lead
to asking the question of how the DHQS enzyme will function if Tyrosine is
incorporated at position 264 and 184.

2.4 Exploration of Activity of Tyrosine as Chelator by DHQSE184Y and DHQSH264Y
mutant
As demonstrated in the growth test shown in figure 2-4 A and B above the
DHQS mutants showed little activity if HQAla was incorporated. Analysis of the
protein expression with and without the HQAla showed there was non-specific
incorporation by the HQAlaRS. It is likely that the amino acid incorporated was
Tyrosine, due to the original template of the HQAlaRS. To test whether Tyrosine
had any ability in chelating the divalent metal, two additional mutants were made:
DHQSE184Y (pJF-aroBE184Y) and DHQSH264Y (pJF-aroBH264Y) (Section4.6). As Tyrosine
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could only potentially donate one electron pair for chelation, unlike HQAla, the other
residue remained at the wild type residue to facilitate the chelation of Co2+.
These mutants were then transformed into the JWΔaroB strain and used in a
growth test in M9 minimal media following the same experimental procedures as
described previously except time points were 0hrs, 24 hrs, and 48 hrs (Figure 2-6 A
and B).
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Figure 2-6A: Growth of JWΔaroB/ DHQSE184Y at 37°C in M9 Minimal Media without
aromatic amino acids and vitamins unless noted.
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Growth test of DHQSH264Y in JWΔaroB
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Figure 2-6B: Growth of JWΔaroB/ DHQSH264Y at 37°C in M9 Minimal Media without
aromatic amino acids and vitamins unless noted.
Though the H264Y mutants had higher activity there was no significant
improvement in activity. The OD over 3 days remained low, with no significant
bounce back. This set of experiment showed that though the HQAlaRS was
incorporating tyrosine, from solution it did not result in restoring activity. Overall it
is likely the unAA HQAla is too large, causing mis-folding, and Tyrosine is unable to
act as a chelating residue to replace either H264 of E184.
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2.5 Growth of Histidine Analogue, 2-(5-bromothineyl)alanine, at metal
Chelating Site H264
As we attempted to mutate the Histidine into a completely different amino
acid analogue, the activity drastically decreased. When introducing a histidine
analogue at position 264 in the active site, an attempt to reestablish proper folding
and metal chelation was made. This unAA could potentially restore some activity to
the enzyme. The histidine analogue used in this experiment was 2-(5bromothienyl)alanine (BrTha) (Figure 2-7).

This unnatural amino acid was

purchased from Chem-Impex International and the selection process for an aaRS to
charge this unAA is described in section 3.2.

Figure 2-7: L-2-(5-bromothienyl)alanine (BrTha) structure
To set up the plasmids for this mutant was not simple. As the vector with the
aaRS encoded does not contain the tRNA to suppress the Amber nonsense codon,
the tRNA was moved onto the pJF vector. This gene was inserted by SLIC (Sequence
and Ligation Independent Cloning) cloning downstream of the aroB gene on the pJF
vector, due to problems in amplification extra non coding sequence was required to
be added before and after the tRNA. The final vector was pJF118EH-aroBx-PylT (x=
being codon of TAG) (Section 4.6). As the 264 position was once a histidine this
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position was chosen for incorporation of the histidine analog.

This mutant was

made by overlapping PCR to incorporate the aroBE184A/H264TAG into the pJF118EHaroBX-pylT forming pJF118EH-aroBE184A/H264TAG-PylT.
This mutant was then co-transformed with the BrThaRS encoding sequence,
pBK-BrThaRS4, into JWΔaroB and used in a growth test in M9 minimal media using
the same experimental procedures as described previously (Figure 2-8).
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Figure 2-8: Growth of JWΔaroB/DHQSE184A/H264TAG at 37°C in M9 Minimal Media
with BrTha without aromatic amino acids and vitamins unless noted.
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2.6 Conclusion
Though there were efficient mechanisms to incorporate HQAla into the
DHQS, no functional protein were produced with restored enzyme activity. In rich
media it appeared that the HQAlaRS incorporated tyrosine or with small amounts of
the HQAla. With either HQAla or tyrosine incorporated into either the 184 or the
264 sites, neither showed any major gain toward restoration in the enzyme activity.
The biggest apparent problem for the HQAla incorporation into DHQS is the
constrained active site. Changing the DHQS active site for the HQAla to be a better
fit would be a potential route to increase incorporation of HQAla. However as the
DHQS catalyzes multiple reactions, finding the space for HQAla and maintaining the
catalytic activity might be a bigger issue.
The incorporation of histidine analogues into the active site seems to be,
potentially, a more useful route. As histidine was already at the 264 site by
incorporating analogues at this position might create a better understanding in how
divalent metal ion facilitates hydride transfer from C5 to NAD+ as well as proton loss
of the C5 hydroxyl. However there are very few histidine analogues that have been
shown to be successfully incorporated into proteins.
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Chapter 3
Histidine Analogue Incorporation for Acid/Base catalysis in DHQS

3.1 Introduction
Though the oxidation catalyzed by the divalent metal in the DHQS is
interesting, it is not the only residue involved in the oxidation of the C5 alcohol. The
Histidine 275 of the Aspergillus nidulans DHQS acts as a proton acceptor in the
acid/base reaction that allows for the oxidation. By changing the basicity of this
residue, the reaction rate of this first step would be altered. Histidine analogs are a
potential unAA to genetically incorporate as the electronics can be varied, but the
relative structure would remain the same.
Currently there are not many histidine analogs that can be used for genetic
incorporation by an aaRS,28 and fewer that can be incorporated into protein using
the amber suppression method,22,22 especially compared to tyrosine analogues. To
expand the tools that scientists can use would be extremely beneficial, especially as
cells often use histidine in catalysis. The process, however, to find a good
tRNA/aaRS pair to recognize these analogues is difficult.
Only a few notable experiments have been done incorporating a histidine
analog by amber suppression. In 2014 the Schultz group showed an incorporation of
3-methyl-histidine, 2-furyl-alanine, 3-(2-thienyl)-alanine and 2-(5-bromothineyl)alanine.21 These unAA were incorporated using a selected MbPylRS that was initially
evolved for the incorporation of 3-methyl-histidine and polyspecific in recognition
of unAA, with relatively high efficiency towards the ones mentioned above.21 In the
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same year, the Soll group published a paper showing a polyspecific MbPylRS able to
incorporate 2-(3-bromothineyl)-alanine22 (BrTha) along with several other tyrosine
analogues. Though the incorporation efficiency of the BrTha was low, it is a step
toward the development in incorporating histidine analogues.

3.2 Library design and selection of tRNA/tRNA synthetase pair for histidine
analogs
There are very little known tRNA/aaRS pairs that incorporate histidine
analogues, but many that can incorporate tyrosine derivatives. There is a great
amount of potential for protein engineering if there were tools to incorporate
histidine analogs as often histidine is found in active site with key roles in catalysis.
As there has been success in two separate projects incorporating the histidine
analogue using an MbPylRS library we used a similar library to get specific
incorporation of a histidine analogue rather than selection for a polyspecific aaRS.
Using the 3N MbPylRS library in our lab, we selected for MbPylRS mutants
that were able to charge tRNAPyl with the following histidine derivatives: 2-(5bromothienyl)alanine (1), 2-mercapto-L-histine (2), diiodo-histine (3), and 2-(5carboxythienyl)alanine (4) (Figure 1-5).

The 2-(5-carboxythienyl)alanine was

newly synthesized by myself and is based off of the Copper (I)-thiophene-2carboxylate (CuTC) complex, which is a good metal chelator, particularly to copper.
The 3N library has randomized sites at Leu270, Tyr271, Leu274, and Cys313. The
Tyr349 was fixed to Phe as it has been previously shown to increase the
aminoacylation with tRNA.29
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Each histidine analogue was used in making GMML selection plates at 2mM
concentrations; the GMML as described in section 1.2 was used to reduce the
potential background.

As minimal media was used, the plates needed to be

incubated for 2 days at 37°C as the growth of the cells were reduced. For the 2mercapto-L-histine in the first round of selection at Cm concentration of 34 μg/mL,
there were only four fluorescent colonies, therefore potential hits. After replication,
however, all colonies showed to be false positives. As for the diiodo-histine, it
showed 15 potential hits after the first selection at Cm concentration of 34 μg/mL,
however they were also all false positives. The 2-(5-carboxythienyl)alanine was also
used with the 3N library and though there were 12 potential hits after the first
round at Cm concentration of 34 μg/mL, none of them were real hits.
The 2-(5-bromothienyl)alanine, however had five successful hits out of the
34 potential colonies. The plasmid containing the aaRS (pBK-MbPylRS) was isolated
and sent for sequencing (Figure 3-1). Looking at the sequence of each mutant
showed unique sequence compared to the polyspecific aaRS published by the
Schultz group.21 These plasmids were co-transformed with the reporter plasmid
pLei-GFP149TAG and inoculated into three cultures, LB non induced, LB induced 0.5
mM IPTG, and LB induced 0.5 mM IPTG with 2mM of 2-(5-bromothienyl)alanine.
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249

Position

270

271

274

313

Polyspecific
aaRS21

Ile (I)

Phe (F)

Gly (G)

Phe (F)

wt

Leu (L)

Tyr (Y)

Leu (L)

Cys (C)

Thr (T)

Phe (F)

Ala (A)

Phe (F)

Phe (F)

ACG

TTT

GCG

TTT

TTT

Leu (L)

Phe (F)

Val (V)

Met (M)

CTT

TTT

GTG

ATG

TTT

Leu (L)

Phe (F)

Thr (T)

Leu (L)

Phe (F)

TTG

TTT

ACG

CTT

TTT

Val (V)

Phe (F)

Ala (A)

Met (M)

Phe (F)

GTG

TTT

GCT

ATG

TTT

Gly (G)

Phe (F)

Asp (D)

Ser (S)

Phe (F)

GGG

TTT

GAT

TCG

TTT

Phe (F)

Tyr (Y)

hit-2

Phe (F)

hit-3

hit-4

hit-6

hit-8
Table 3-1: Sequencing of randomized codon for 3N MbPylRS library hits charging 2(5-bromothienyl)alanine (BrTha).
All five hits were strongly florescent with the addition of the unAA, 2-(5bromothienyl)alanine. The fluorescent signal of each culture was normalized by the
number of cells in that culture. This normalized fluorescence of the induced culture
without unAA was compared to the induced culture with unAA. The larger the ratio
of the induced culture to the induced culture with unAA correlated to a higher
specificity of the aaRS towards the BrTha. The largest ratio of the induced culture
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with the unAA to the induced culture without unAA was mutant 4 (Figure 3.2). As
the mutant 4 had the highest specificity to BrTha, it was used in the DHQS
experiments. These synthetase mutants were then tested for the incorporation of
other

histidine

analogues,

mercapto-L-histine,

diiodo-histine,

and

2-(5-

carboxythienyl)alanine. However none of these mutants were able to show
indication of incorporation of the other unAA.

Mutant

Fluorescence (RFU)

Normalized Fluorescence
(RFU/OD)

Ratio

non

i

i +BrTha

non

i

i+ BrTha

(i+BrTha)/(i)

2

265

663

9212

128.3

348.0

6533.3

18.7

3

61

121

5452

21.7

84.3

2931.2

34.7

4

26

51

6020

9.7

20.4

2887.3

141.5

6

79

109

5339

41.4

83.5

2591.7

31.0

8

62

124

3614

23.7

69.5

2007.8

28.9

Table 3-2: Incorporation efficiency of MbPylRS hits towards BrTha. [(non) – non
induced culture; (i) – induced with 0.5mM IPTG; (i + BrTha) – induced with 0.5mM IPTG
and 2mM 2-(5-bromothienyl)alanine]

As mutant 4 (designated as BrThaRS) was able to charge tRNAPyl with 2-(5bromothienyl)alanine efficiently, it was used as a template for the construction of a
new error-prone PCR library. We hope we can identify MbPylRS mutants from this
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library for the genetic incorporation of other histidine analogues that are not
recognized by the MbPylRS mutants in the 3N library.

Instead of mutating

particular codons, the whole aaRS was randomized through a random mutagenesis
enzyme, mutazyme. By using this enzyme in amplification of the gene, random
errors could occur along the whole sequence. Small changes in the sequence can
cause the ability for a synthetase to change its ability to bind a particular amino acid.
In the example of selection a TyrRS mutant to bind para-acetylphenylalanine, the
Schultz group found a small change in the location of an alpha helix at the back of
the binding pocket affected specificity greatly.30 Overall, small changes in the folding
of the BrTharRS could increase binding of other histidine analogs.
After amplifying the BrThaRS with a mutazyme, the amplified sequence was
cloned into the pBK vector. This mutazyme made small errors randomly as during
each round of amplification. The exact size of the library could not be determined as
the mutagenesis is random. The library was then transformed into the reporter
strain via electroporation.

This newly constructed random mutagenesis (RM)

library, BrThaRSRM, was then used for selection against mercapto-L-histine, diiodohistine, and 2-(5-carboxythienyl)alanine. No positive hits were obtained for the
diiodo-histidine. The selection against mercapto-L-histine resulted in three weak
hits, whereas the 2-(5-carboxythienyl)alanine selection resulted in two weak hits
(Figure 3-3).
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Figure 3-1: Selection of libraries, BrThaRSRM and 2-mut library against mercapto-Lhistine, diiodo-histine, and 2-(5-carboxythienyl)alanine
Two other libraries including the WN1, and the 2-mut library, both
constructed by Dr. Wei Niu in our lab, were used in selection for the genetic
incorporation of other histidine analogues.

Unfortunately, no hit was identified

from the WN1 library. Though the 2-mut library had three weak hits for the
mercapto-L-histine, and one for the 2-(5-carboxythienyl)alanine, there were none
for the diiodo-histidine (Figure 3-1). Over the selection process it appeared that the
diiodo-histidine is slightly toxic, as there are significantly less colonies that were
able to grow, often only up to ten or twenty in comparison to the other selection
plates, which grew over a hundred colonies.
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As the results from the PylRS selections showed no hits for the incorporation
of the other histidine analogues, finding ways to develop a new library to
incorporate, specifically, histidine analogues would be beneficial. Previously with
the random mutagenesis library, it was hoped that minor changes in folding would
result in recognition of the other histidine analogues. But as the work of the Soll
group gave some understanding of the mechanism of binding of the 2-(5bromothienyl)alanine for their polyspecific PylRS;22 perhaps crystallization of our 2(5-bromothienyl)alanine could also give some insight in how the synthetase binds
histidine analogues.
As crystallization of proteins can give in-depth understanding of how a
protein interacts with a substrate, to crystallize BrThaRS would be helpful in
determining which codons to randomize to make new libraries for the incorporation
of histidine analogs. With a collaboration with the Dr. Wilson lab in the Department
of Biochemistry of UNL, we started on the process of crystallizing our BrThaRS that
charges 2-(5-bromothienyl)alanine.

In previous work, all PylRS structures are

crystalized from the MmPylRS, therefore any hits from MbPylRS libraries are
analyzed and analogous residues are mutated on the wild-type MmPylRS to match it.
As there is no structure for the MbPylRS, we decided to see if we could crystallize
our BrThaRS mutant, a derivative of MbPylRS, and develop a method for its
crystallization.
The MmPylRS and the MbPylRS are very similar; thereby we designed the
expression vector for the BrThaRS much like what was has been reported
previously for the MmPylRS. To this end, we inserted the PylRS gene into the
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pET28b vector with a C terminus His tag installed.31 As often, there are issues in
solubility of full length proteins, we also amplified a truncated version of the
BrThaRS mutant that still maintains the structural components of the active site
(Section 4.6). After cloning the amplified sections of the BrThaRS gene into the
pET28b vector these plasmids were transformed into the host BL21(DE3) to ensure
high protein production.
E. coli BL21(DE3) strain harboring plasmid pET28b-BrThaRS (full-length or
truncated version) was cultured in 1 L LB media containing kanamycin. The protein
expression was induced by the addition of 1.5 mM IPTG. After overnight growth at
room temperature, cells were collected and lysed. Both the full length and the
truncated proteins were purified using Ni2+ Sepharose 6 Fast Flow resin (GE
Healthcare). As shown in the SDS-PAGE analysis (Figure 3-2A and B), a large amount
of protein was obtained with high purity. It was found that by keeping the salt
concentration at 500mM but removing phosphate and imidazole from solution the
protein remains soluble. Therefore there is enough to begin process of
crystallization.
FT

BB

W1

W2

E1

E2

E3

Figure 3-2A: pET28b-BrThaRSfull length expressed in BL21(DE3) cells.
Protein size 49.7 kDa
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Figure 3-2B: pET28b-BrThatruncated expressed in BL21(DE3) cells. Protein
size 33.3 kDa

3.3 Construction of DHQS mutant and expression plasmid
For this work, emphasis on the DHQS and how protein engineering could
help understand the mechanism, and affect the activity of the enzyme, was key.
Focusing on another active histidine, we mutated the His 251 codon to the Amber
nonsense codon. This 251 site is analogous to the 275 site shown on the crystallized
DHQS, as published by the Brown group.18 Using overlapping PCR this site, H251,
was mutated to the Amber nonsense codon. This position would be interesting to
examine because of its role as a Lewis base in the oxidation process of the C5 oxygen
of DAHP.
As previously described, a tRNA suppresses this nonsense codon in the
ribosome by the incorporation of an unAA. As our selection process uses the pBK
plasmid to encode the aaRS library, there is no tRNA sequence encoded. As the aaRS
needs a tRNA that recognizes the nonsense codon, this was installed downstream of
the aroB sequence on the pJF plasmid (Section 4.6). Initially the tRNA sequence was
to be installed via SLIC cloning with minimal excesses non-coding sequence.
However amplification and annealing of the minimal tRNA insert proved to be
difficult. So the amplified sequence was expanded to include noncoding sequence,
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allowing for the successful cloning of the tRNA into the pJF-aroBH251TAG plasmid
forming pJF118EH-aroBH251TAG-pylT.

This expanded plasmid was used for the

incorporation experiments with 2-(5-bromothienyl)alanine.

3.4 Growth test of His 251 site mutant of DHQS
While we were only able to genetically incorporate one histidine analogue, 2(5-bromothienyl)alanine, we decided to use it to probe the catalytic role of His251
of DHQS. After co-transforming both plasmids, pJF118EH-aroBH251TAG-pylT and pBKBrThaRS into the JWΔaroB strain, the cell growth was monitored in the same way as
described in the metal chelating mutant experiments. OD was taken after 12 hours,
24 hours, and 48 hours (Figure 3-3). As there was significant jump in growth after
48 hours the cultures were incubated longer till 114 hours.
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Growth test of DHQSH251TAG in JWΔaroB
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Figure 3-3: Growth of JWΔaroB/ DHQSH251TAG at 37°C in M9 Minimal Media without
aromatic amino acids and vitamins.
The DHQS mutant with the BrTha incorporated at the 251 site had an overall
lower activity than the wild type DHQS as growth was only seen after about 72
hours. Though this result was promising there was the issue that the induced
culture (without unAA) grew more rapidly in the first 48 hours, though plateaued
later. As DHQS should be truncated if there is no 2-(5-bromothienyl)alanine added,
this means the synthetase is incorporating some other amino acid. As there was
growth in the induced cultures (with or without unAA), the sequence of each culture
was checked after the 114 hour incubation. The initial inoculating culture, the
induced culture, and the induced + BrTha + trace elements were compared to see if
there were any mutations (Figure 3-4).
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(A)

(B)

(C)

Figure 3-4: Codon sequencing of H251 (A) inoculating culture (B) induced culture,
(C) induced culture + 2-(5-bromothienyl)alanine + trace elements
Comparing the sequence of the three cultures showed interesting results, as
the induced culture (without unAA) had no mutations and the TAG codon remained
unchanged from the initial culture. The induced culture + BrTha+ trace elements,
however, showed that there was a mutation from TAG to CAG at about a 60:40 ratio.
A mutation to this codon was unexpected, as there is no pressure for mutation with
the 2-(5-bromothienyl)alanine in solution.

This codon mutation was seen

repetitively in multiple grow tests, as such it is hypothesized that it is an error was
introduced during the construction of the aroBH251TAG mutant. To purify the culture,
the initial culture was streaked out and a single colony was selected. This isolated
plasmid was transformed into Genehog. This process was repeated twice more with
the final resulting plasmid sent for sequencing. This plasmid was co-transformed
into the JWΔaroB host with pBK-aaRSBrH4 and the growth test was repeated
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(Figure 3-5). After 66 hours all the cultures began to grow including the induced
culture without the unAA. Again the cultures were isolated to check if the codon
mutated again, however this time all cultures were the same as the induced culture
(Figure 3-6).

Growth Test of Purified pJF-aroB(H251TAG)
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+TE
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0
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Figure 3-5: Growth test of purified pJF-aroBH251TAG plasmid in JWΔaroB strain
grown at 37°C in M9 Minimal Media without aromatic amino acids and vitamins.
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(A)

(B)

Figure 3-6: Sequence of (A) induced culture and (B) induced culture + 2-(5bromothienyl)alanine + trace elements
With the culture without the unAA still growing to a similar level to the
culture with the unAA, the pJF plasmid was tested by itself without the synthetase.
Rationally if there was no synthetase to charge amber suppresser tRNA, then when
the culture is induced the DHQS would be truncated and nonfunctional.
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Transforming the pJF-aroBH251TAG by itself into the JWΔaroB strain the mutant was
monitored during the growth test (Figure 3-7). With no synthetase being coexpressed, the fact that the culture still grew indicated a fault with the plasmid
designed or with the strain used. To test this, we used the second knockdown strain
of AB2847. This strain still has an aroB gene though the specific activity of its
encoded protein is much reduced. After co-transforming the pJF-aroBH251TAG and the
pBK-BrThaRS together this mutant was examined in a similar growth test as
described before (Figure 3-8).
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Figure 3-7: Growth test of purified pJF-aroBH251TAG in JWΔaroB strain grown at 37°C
in M9 Minimal Media (non: non induced ) (i: induced).
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Growth test of DHQSH251TAG in AB2847
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Figure 3-8: Growth test of purified pJF-aroBH251TAG-pylT in AB2847 strain grown at
37°C in M9 Minimal Media without aromatic amino acids and vitamins.
From this data, overall it showed that there was an issue of the pJFaroBH251TAG-pylT. This is significantly noticeable as moving hosts and induction by
itself results in growth of the culture was observed in the absence of BrThaRS. It is
unclear why this phenomenon was occurring, as the same vector and construct
design was used with the mutants DHQSE184TAG/H264A and DHQSE184A/H264TAG and this
issue was clearly absent there. Comparing the amount of protein by western blot
shows that a small amount of DHQSH251TAG is expressed in the presence of unAA, but
no noticeable amount of protein is expressed in the induced cultures without unAA.
Therefore, since there is an amount expressed, this mutant is still used for the
activity assay in section 3.5.
Lastly, in the interest of why the codon mutation from TAG251 to CAG251
happened and if this glutamine has any effect in restoring activity, another mutant
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pJF-aroBH251CAG-pylT was constructed using overlapping PCR from the pJFaroBH251TAG-pylT vector (Section 4.6). This plasmid was then co-transformed into
the JWΔaroB strain for comparison to the DHQSH251TAG enzyme to see the activity
difference. After setting up the growth test in the same manner as previously
discussed, surprisingly, the DHQSH251Q showed to have high activity, growing
significantly after 24 hours (Figure 3-9). As this mutation showed to restore a
significant amount of activity, this enzyme was used for the activity assay in section
3.5 as well. Though this mutant was shown to restore activity it is not clear why as
the glutamine should not be able to act as a Lewis base needed for the oxidation of
the C5 alcohol of DAHP.
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Figure 3-9: Growth test of mutant pJF-aroBH251CAG plasmid in JWΔaroB strain grown
at 37°C in M9 Minimal Media without aromatic amino acids and vitamins unless
noted.

3.5 Activity Assay of DHQSH251TAG
To compare the relative activity of DHQSH251BrTha, to the activity of the
DHQSwt both enzymes were purified and assayed. The assay is based on the Piper
Phosphate Assay that measures the amount of inorganic phosphate in a solution.
This is because the DHQS releases a phosphate into solution during the catalysis of
DAHP to DHQ. As such, the activity of the DHQS variants can be determined based
off of how much phosphate is released into the solution.
This assay was prepared by first incubating the DHQSwt, DHQSH251BrTha, and
the DHQSH251Q with approximately 50 mM of DAHP.32 The concentration of DAHP
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was an estimated value that was based on 1H NMR integration (Section 4.5). The
assay was conducted in a buffer containing 50mM MOPS pH 7.75, 50 μM cobalt (II)
Zinc, 10 μM NAD+.32 The assay mixture was incubated at room temperature for 30
minutes in a 96 well plate. 32 After incubation, the reaction was diluted with 50 μL of
the Piper Phosphate Assay solution and incubated for another 30 minutes at 37°C.
The absorbance of each reaction was taken at 563 nm, as this is the absorbance of
Amplex Red formed at the end of the Piper Phosphate Assay. Unfortunately this
assay was gave inconsistent results. This was probably due to the extra phosphate
in the purified DAHP.
As the Piper Phosphate Assay was not consistent, we decided to use the
Couple Enzyme Assay. This was based of the 1997 paper by Frost, the basic buffer
solution described above: a buffer containing 50mM MOPS pH 7.75, 50 μM cobalt
(II) Zinc, 10 μM NAD+. As 3-dehydroshikimate has an absorbance at 234 nm, the 3dehydroquinate dehydrate is used in this couple enzyme assay. 0.1 mg of dehydrate
is suspended in a solution with DAHP and incubated at room temperature for 5
minutes. Then 0.02 mg of the DHQS mutant is added and the absorbance is
monitored over the first 90 seconds (Figure 3-10). Calculating the specific activity of
the enzymes, we got the approximate values of 0.625 μmol mg-1 min-1 for DHQSwt
and 0.327 μmol mg-1 min-1 for DHQSH251TAG. The DHQSH251Q was assayed using this
same assay however the results were inconsistent. The DHQS of the mutant was half
that of the wild-type leading to the reduced activity. The significant lack of growth
was probably due to the instability of the BrTha during the catalysis conditions.
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Figure 3-10: Absorbance of 3-dehydroshikimate from the couple enzyme assay of
DHQS and 3-dehydroquinate dehydrate.

3.6 Conclusion
In summary all the experimental data shows that incorporation of unAA at
the His251 site that there is greater potential in effecting the activity of the DHQS.
Though the activity of the DHQS decreased after incorporation of the BrTha, this
was expected. As the bromo-thienyl group acts as a weaker base it should be less
likely to catalyze the deprotonation of the C5 hydroxyl group. Finding that the
replacement of histidine to glutamine maintained the enzymatic activity was
surprising. As the amide group acts as a poor Lewis base at neutral and acidic pH,
this might say a bit about the relative pKa of the active site. Or there are more
residues that assist in the acid- base catalysis. Overall using histidine analogues
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would allow a systematic probing of the active site and the mechanism of the E. coli
DHQS.

This highlights the importance of developing a system to genetically

incorporate histidine analogues as a method to probe the catalytic mechanism, both
for this enzyme as well as other enzymes that has histidine in the active site.

Chapter 4
Experimental Methods and Procedures

4.1 Introduction
To prepare the amino acid analogues, plasmids, and substrates used for the
experiments described above they were synthesized/constructed in as described in
this chapter. The two major synthesis projects were the HQAla synthesis mainly
based of the Fridkin work. Another synthesis project was the synthesis of 2-(5carbozylthienyl)alanine. The last synthesis project described was the attempts at
synthesize a diazarine-theronine derivative, photo-threonine. The DAHP which was
used in qualifying the enzyme activity of the DHQSwt, DHQSH251BrTha, and DHQSH251Q;
was isolated, as described, from the knockout strain AB2847. Lastly this section
addresses the construction of the various plasmids used in this work.
1H

NMR spectra were recorded on a 300 MHz spectrometer. Chemical shifts

for 1H NMR spectra are reported (in parts per million) relative to internal
tetramethylsilane (Me4Si, δ = 0.0 ppm) with CDCl3 as solvent and to sodium 3(trimethylsilyl)propionate-2,2,3,3,-d4 (TSP, δ = 0.0 ppm) when D2O was the solvent.
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Silica gel was used for flash chromatography. Analytical thin-layer chromatography
(TLC) utilized precoated plates on silica gel 60 F-254. TLC plates were visualized by
UV or chemical stains. Distilled, deionized water was used to prepare all aqueous
solutions. Organic solutions of products were dried over anhydrous agents, such as
Na2SO4.

4.2 Hydroxyquinolin-alanine synthesis and experimental data

Scheme 4-1: Synthetic route for hydroxyquinolin-alanine (HQAla).
This section addresses the synthesis of the unAA hydroxyquinolin-alanine
(HQAla) and synthetic optimizations made in the methodology.
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(1.A)

(2.A)

Scheme 4-2: Synthesis of 5-chloromethyl-8-quinolinol33 (2.A)
70 mmols 8-quinolinol (1.A) was added to 4.4 mmol of Zinc Chloride, and 7 mL 40%
Formaldehyde and 50 mL of 12 N HCl. After allowing reaction to stir at room
temperature for two days the reaction was filtered and washed with acetone until
flow through ran clear. Two days were used instead of one day as yield was
significantly higher increased to by 10%. Increasing the concentration of
formaldehyde from 20% to 40% improved final yield to 90%
Yield 90%: 1HNMR in D2O: δ 9.18 (d, 1H), 8.90 (d, 1H), 7.98 (m, 1H), 7.64 (d, 1H),
7.30 (d, 1H), 4.96 (s, 2H).
Though the Fridken group described this transformation they used HCl gas,
which is particularly dangerous to handle. This method was selected as the yield is
still high but the methodology is much safer.
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(2.A)

(3.A)

Scheme 4-3: Synthesis of 8-(5-chloromethyl)quinolyl acetate26 (3.A)
1 mmol of 5-chloromethyl-8-quinolinol (2.A) was placed under N2 atmosphere and
dissolved in 5 mL DMF. The flask was then cooled to 0° C on ice and 2.5 mmol of
pyridine and 8mmol acetyl chloride was added simultaneously drop wise under
nitrogen. If added too fast total yield of the reaction will decrease significantly. The
reaction was stirred for 1 hour at 0° C, then 1 hour at room temperature. The
reaction was then cooled to 0° C and 1.1 mmoles of cold water was added and
allowed to stir for 20 minutes to quench the reaction. The product was extracted by
a chloroform wash (3x20mL) and the organic layers were combined. The organic
layer was dried using saturated NaHCO3 (2x20mL) and brine (2x20mL). The solvent
was removed by evaporation to yield 8-(5-chloromethyl)quinolyl acetate (3.A) about
80% of product though crude.
Yield 80% (crude): 1HNMR in CDCl3: δ 9.05 (d, 2H), 8.62 (d, 2H), 7.65 (d, 4H), 7.64
(d, 2H), 5.02 (s, 4H), 2.57 (s, 5H).
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(3.A)
Scheme

(4.A)
4-4:

Synthesis

of

diethyl

(8-hydroxyquinolin-5-yl-methyl)-

acetamindomalonate26 (4.A)
0.762 mmols of 8-(6-chloromethyl)quinolyl acetate (3.A) in minimal amounts of
chloroform. 0.842 mmols of diethyl amidomalonate was dissolved in dry ethanol
with an equal mole amount (.842 mmols) of metallic sodium. After all sodium was
dissolved the ethanol solution was added to the 8-(6-chloromethyl)quinolyl acetate
solution and allowed to reflux for 8 hours. After completed the ethanol was removed
by evaporation 20 mL of water was added to re-solubilize. The product was
extracted with 1:1 ethylactate:chloroform (2x20mL) and washed once with brine
(10mL) and dried over Na2SO4. If more than one wash of brine is used then solution
becomes miscible and product cannot be removed. The ethylacetate:chloroform
solution was evaporated off to get crude diethyl (8-hydroxyquinolin-5-yl-methyl)acetamindomalonate (4.A). Product cannot be purified.
Yield 59% (crude): 1HNMR in CDCl3: δ 8.77 (d, 1H), 8.33 (s, 1H), 7.43 (m, 1H), 7.13
(m, 1H), 6. 45 (s, 1H), 4.25 (m, 4H), 4.04 (s, 2H), 1.88 (s, 3H), 1.30 (t, 7H).
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(4.A)

(5.A)

Scheme 4-5: Synthesis of 3-(8-hydroxyquinolin-5-yl)alanine26 (5.A)
21.9 mmol of the diethyl (8-hydroxyquinolin-5-yl-methyl) acetamindomalonate
(4.A) with 150mL of 9 N of HCl and allowing it to reflux for 9 hours. In reference it
was suggested 6N of HCl to be used for deprotection, but higher yield of the
deprotection was seen when the concentration was raised to 9N. The HCl was
removed by evaporation and then the solid was re-dissolved in water. The water
then was adjusted to pH 5 - 5.5 with 10% sodium hydroxide. At this time a yellow
precipitate is formed and it is then washed with water adjusted to pH 5.5 and then
acetone. The precipitate is recrystallized in water pH 5.5 to give final product 3-(8hydrozyquinolin-5-yl)alanine (5.A).
Yield 65%: 1HNMR in D2O: δ 8.74 (d, 1H), 8.48 (d, 1H), 5.57 (m, 1H), 7.33 (d, 1H),
7.06 (d, 1H), 3.92 (m, 1H), 3.68 (m, 1H), 3.27 (m, 1H).

71
4.3 2-(5-carboxylthienyl)alanine synthesis and experimental data

Scheme 4-6: Synthetic route for 2-(5-carboxylthienyl)alanine
The unAA 2-(5-carboxylthienyl)alanine is a new compound and has potential
for incorporation into proteins. This new molecule was a hopeful for incorporation
into the DHQS to the H251 or H264 position. Together with other histidine
analogues it would be an interesting addition to examine how histidine and it’s
unique properties can affect enzyme activity. In addition, as both the thionyl group
and carboxyl group can donate electrons, this electron rich histidine analogue has
potential as a metal chelator. This compound can be obtained at high yields and high
purity. Unfortunately, efforts to evolve an aminoacyl-tRNA synthase to incoperate
the unAA failed. In the future, if we can get a crystal structure of BrThaRS, a new
library will be designed and examined for the genetic incorporation of this unAA
and other histidine analogues.
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(1.B)

(2.B)

Scheme 4-7: Synthesis of 5-methylthiophene-2-carboxylate34(2.B)
0.925 mL of 2-methylthiophene (1.B) was added to dried flask and flushed with Ar.
12 mL of dry THF was added to flask then cooled to -10 C. 8 mL of n-butyllithium
(1.6 M in hexanes) was added slowly and stirred for 5 hours at -10 C. After, 1.44 mL
ethyl chloroformate was added to 10 mL of dry THF and cooled to -10 C. Ethyl
chloroformate mixture was added drop wise to 2-methylthiophene solution.
Removed from dry ice bath and allowed to stir at room temperature overnight.
The reaction was poured over ~ 50 mL of ice and stirred at room
temperature until ice melted. Water extracted; then 25 mL of 1M HCl used to wash
reaction. Washed reaction with 25 mL of saturated sodium carbonate solution.
Washed reaction with 25 mL of water then dried with sodium sulfate. Concentrated
product under vacuum. Purified by silica flash column (1:9 Ethyl Acetate: Hexanes).
Yield 71%: 1H-NMR in CDCl3: δ 1.358 (t, 3H), 2.519 (s, 3H), 4.320 (q, 2H), 6.758 (d,
1H), 7.605 (d, 1H).
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(2.B)

(3.B)

Scheme 4-8: Synthesis of Ethyl 5-bromomethylthiophene-2-carboxylate35 (3.B)
0.638g of 5-methylthiophene-2-carboxylate (2.B) and 1.022g of NBS added in dried
flask. 10 mL of carbon tetrachloride was added and a catalytic amount of AIBN
added. Refluxed 2 hours at 94°C, then another catalytic amount of AIBN added and
refluxed for another 2 hours. Removed from heat and filtered. Purified by flash
column with 1:9 (Ethyl Acetate: Hexane).
Yield 82%: 1H-NMR in CDCl3: δ 1.368 (t, 3 H), 4.344 (q, 2H), 4.673 (s, 2H), 7.086 (d,
1H), 7.630 (d, 1H).

(3.B)
Scheme

4-9:

(4.B)
Synthesis

of

2-acetamido-2-((5-(ethoxycarbonyl)thiophene-2-

yl)methyl)malonate36 (4.B)
0.861 g (3.96 mmol) of diethyl acetamidomalonate suspended in 8 mL of dry
DMF and cooled to 0°C; 0.190 g (2 eq.) of NaH added and flask flushed with Argon.
Warmed to room temperature and stirred for 20 minutes. 0.891g (3.57 mmol) of
ethyl 5-bromomethylthiophene-2-carboxylate (3.B) was added and stirred
overnight at room temperature. Reaction quenched with 10 mL of dH 2O and
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extracted with ether (16mL x 3) washed with brine and dried over MgSO4 and
concentrated. Next step proceeded without purification.
1H-NMR

δ 1.368 (3 H, t, J = 7.2 Hz, CH2CH3), 4.344 (2 H, q, J = 7.2 Hz, CH2), 4.673 (2

H, s, 5 – BrCH2), 7.086 (1H, d, J = 4 Hz, 4-H), 7.630 (1 H, d, J = 4 Hz, 3-H)

(4.B)

(5.B)

Scheme 4-10: Synthesis of 2-(5-carboxylthienyl)alanine (5.B)
1.334g

of

impure

diethyl

2-acetamido-2-((5-(ethoxycarbonyl)thiophen-2-

yl)methyl)malonate (4.B) was dissolved in 100 mL of 4M HCl and refluxed for 4
hours. Removed from heat and stirred overnight at room temperature.
Concentrated and re-suspended in dH2O and extracted with ethyl acetate
then concentrated.
Yield 70% 1H-NMR in D2O: δ 3.53 (dd, 2H), 4.186 (t, 1 H), 7.09 (d, 1H), 7.74 (d, 1 H).
13C-NMR

in D2O: δ 30.5, 53.48, 129.54, 133.18 135.10, 143.85, 165.34, 170.5
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4.4 3O-diazirin-L-threonine synthesis and experimental data

Figure 4-1:

Structure of 3O-diazirine-L-threonine (photo-threonine)

Attempts were made to synthesize the threonine analogue, 3-diazirin-Lthreonine (Figure 4-11). The diazirine functionality of this unAA would have the
ability to cross-link through a light induced carbene formation. Previous unAA have
been designed with the diazarine functionality including 4’-[3-(trifluormethyl)-3Hdiazirine-3-yl]-L-phenylalanine (A) 37 , L-photoleucine 38 (B), L-photomethionine
(C)38, 39 L-photoproline (D)40 (Figure 4-12).

The proposed structure would be the

smallest unAA with this diazirine functionality, and would be ideal for incorporation
into an active site to replace catalytic cysteine or serine. This was a collaborative
project with Dr. Mark Wilson from Biochemistry. Various routes were attempted to
synthesize this unAA however none were successful. The inability to synthesize this
threonine analogue is likely due to the acidic alpha hydrogen, the reactivity of this
hydrogen likely destabilizes the intermediates the diazirine formation.
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(A)

(B)

(C)

(D)

Figure 4-2: Structures of unAA with diazirine functionality: (A) 4’-[3(trifluormethyl)-3H-diazirine-3-yl]-L-phenylalanine, (B) L-photoleucine, (C) Lphotomethione, (D) L-photoproline.
The first synthetic route to this unAA was to create a keto to undergo the
diazirine formation in a similar method described in by the Watanabe group shown
in the synthesis route shown in Scheme 4-11.41 This β-keto-threonine derivative
was obtained at high yields and used in various attempts to form the diazirine
product.

Scheme 4-11: Synthesis route to the β-keto-threonine derivative, Boc-protected βketo-threonine methyl ester.
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(1.C)

(2.C)

Scheme 4-12: Synthesis of L-threonine methyl ester (2.C)
16.8 mmol of L-Threonine (1.C) was weighed out and set aside. 25 mL of anhydrous
Methanol was cooled to 0°C and 30 mL of thionyl chloride was added to the
methanol over 30 minutes then allowed to stir at 0°C for an additional 15 minutes.
The weighed out L-threonine was added slowly to the reaction and allowed to stir
for 30 minutes at 0°C. The reaction was removed from the ice bath and allowed to
stir for 24 hours at room temperature and reaction was checked via TLC (9:1
CH3Cl:MeOH) for formation of (2.C). Solvent removed under reduced pressure.
Yield (Crude) 80% 1H NMR in CHCl3: δ 1.23 (d, 3H), 3.77 (s, 3H), 3.84 (d, 1H), 4.18
(m, 1H)

(2.C)

(3.C)

Scheme 4-13: Synthesis of Boc-protected-threonine methyl ester 41(3.C)
3.0 g of threonine methyl ester (2.C) and 4.607g of NaHCO3 were dissolved in 36 mL
of 1:1 MeOH:dH2O. 5.805g of di-tert-butyl dicarbonate was added slowly over 15
minutes. The reaction was allowed to stir for 24 hours at room temperature. The
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solvent was removed under vacuum and solution acidified to pH 4.5 with 1M citric
acid. Product (3.C) was extracted with 4 mL of ethyl acetate 30 times and solvent
was removed in vacuum.
Yield (Crude) 84% 1H NMR in CDCl3: δ 1.22 (d, 3H), 1.43 (s, 9H), 3.74 (s, 3H), 4.26 (d,
1H), 4.33 (d, 1H), 5.26 (bd, 1H)

(3.C)

(4.C)

Scheme 4-14: Synthesis of Boc-protected β-keto-threonine methyl ester41 (4.C)
1.7 mmol of Boc-protected-threonine methyl ester (3.C) was dissolved in 4 mL of
methylene chloride. 0.5 mM of Dess Martin periodinane (DMP) was added and
reaction allowed to stir at room temperature for 45 minutes. 16 mL of 1:1 NaHCO3:
10% Na2S2O3 added to quench reaction and allowed to stir for 10 minutes at room
temperature. Product was extracted with 30 mL of ethyl acetate three times. Solvent
removed under vacuum. Boc-protected β-keto-threonine methyl ester (4.C) was
purified by 9:1 hexane: ethyl acetate column.
Overall yield 33.5% 1HNMR in CDCl3: δ 1.46 (s, 9H), 2.38 (s, 3H), 3.83 (s, 3H), 5.02
(d, 1H), 5.28 (bd 1H).
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Scheme 4-15: Synthesis of Boc-protected β-diazirine-threonine methyl ester.
To transform the keto group to the diazarine was done following the
procedure outlined in the synthesis of L-photomethione by the Yao group.39 400mg
Boc-protected β-keto-threonine methyl ester (4.C) was dissolved in 5 mL of liquid
ammonia and stirred 7 hours at -78°C. The reaction was cooled to -78°C and 1.2
equivalents of hydroxylamine-O-sulfonic acid in anhydrous methanol was added
drop wise over 30 minutes. The reaction mixture was stirred overnight at room
temperature allowing the ammonia to evaporate off. The reaction was filtered and
washed with methanol. The combined methanol was concentrated to half the
volume and 10 mL of fresh methanol was added then reaction cooled to 0°C. 1.2
equivalents of TEA was added slowly. I2 was added slowly until solution remained
light brown. The reaction was stirred at room temperature for 1 hour and
concentrated. The product was extracted with ethyl acetate. The organic layer was
washed with brine and dried. NMR showed no product formed.
To attempt to get product the procedure was altered slightly in reference to
other papers describing the synthesis of diazirines. Varying the concentration of the
ammonium was altered from 100% by volume to 50% by volume showed no
formation of products. Varying the reaction going for 5 hours, 7 hours, 9 hours, or
12 hours showed no formation of products. Varying the temperature of the reaction
from -78°C, 0°C, or 20°C showed no formation of products. The major problem that
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we predict prevents the formation of the diazirine product is probably the favored
enol formation by the β-keto group. This enol probably is what is preventing the
diazirine formation.

Scheme 4-16: Proposed pathway to photo-threoine via methyl acetoacetate.
As it is likely that the β-keto group is forming an enol intermediate, the amine
protecting group was changed to a pthalimide to change the electronic properties of
this acidic proton. It is key that any protecting groups that are put onto the molecule
could be removed in favorable conditions to the diazarine, as it is sensitive to heat
and reductive conditions. Though the pthalimide was synthesized, the enol was the
major product. However after further reading it was found that the pthalimide
protecting group would favorably form an enol at 100%.42 This pthalimide was
synthesized, and though the enol was the major product, it was used to attempt to
transform the keto group into a diazarine. As expected no product was formed, this
however showed that the enol is not able to undergo the necessary chemistry for
this transformation.
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Figure 4-3: Diazirine-first synthetic approach.
As the alpha hydrogen is so acidic on we attempted to circumvent this route
by adding the diazirine early in the synthesis. Based off of the work by the Behrman
group. 43 Initial experiments to add the diazirine starting from the methyl
acetoacetate did not work. Again this is probably due to the acidy of the alpha
hydrogen.

To reduced the acidity of near the keto group we started with 4-

hydrozybutan-2-one, and preceded to try and build the molecule from the diazirine
molecule. Though the first step was successful, and the diazirine was formed. The
following intermediates decomposed rapidly supporting the theory that the alpha
hydrogen destabilizes the diazirine functional group. Though it is probably possible
to synthesize the photo-threonine if kept in unreactive conditions, it is likely too
unstable to be used in biological conditions.
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4.5 Biochemical Synthesis of DAHP
To test the relative activity of the enzymes evolved in section 3.5, the assay
needed DAHP. The DAHP was biosynthesized by the AB2847 strain in a similar
manner outlined by the Frost group. Transforming a plasmid with the aroF gene on
a Cm resistant vector, this strain was inoculated into an M9 minimal media culture
for overnight incubation at 37°C. Though the Frost group saw excretion of the
DAHP from the AB2847 strain without the addition of the aroF gene, this addition
allows for the suppression of the aroB gene of the Shikimate pathway even in high
presence of aromatic amino acids and vitamins. The suppression should then
produce higher amounts of the DAHP.
This overnight culture was then inoculated into 200 mL of minimal media
prepared as following:
K2HPO4 (1.4 g), KH2PO4 (0.6 g), and (NH2)2SO4 (0.2 g) were dissolved in 200
mL of water and autoclaved.44 5 mL of 20% glucose was then added with 200 μL of
MgSO4 (120mg/mL). Following, L-tyrosine (4mg/mL), L-phenylalanine (4mg/mL),
L-tryptophan solutions (4mg/ml) and L-thiamine (1mg/mL) were made and
purified by filtration through a membrane. Then 400 μL of L-Tyrosine solution, 400
μL of L-phenylalanine solution, 200 μL of L-tryptophan, and 200 μL of L-thiamine
solution were added to the sterile media culture.44 Finally, this sterile solution was
then inoculated with 5 mL of the overnight AB2947aroF culture and incubate at 37°C
for 32 hours.44
Following the Frost paper44: after incubation the culture was spun down and
the supernatant was isolated and run through a 100 mL Dowex 50 H+ column at 4°C.
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The pH of the eluent was adjusted to pH 8.0 with 1M LiOH, lithium hydroxide was
used as the lithium counter ion which allows for easier solubility in alcohols. This
adjusted solution was concentrated and kept at below 30°C. The residue was then
dissolved in 200 mL of methanol and cooled to 4°C. This solution was stirred for 1
hour at 4°C until white precipitate formed. The precipitate was removed via
filtration and the eluent was concentrated under vacuum.

This was then re-

suspended in 200 mL of ddH2O and pH was adjusted to 7.1 with 1M LiOH. The
DAHP and DAH in the solution was purified via a DEAE-cellulose column
equilibrated with 100mM of triethylammonium bicarbonate (TEAB) pH 7.1. These
components were eluted by a gradient of 100mM to 300mM TEAB solution (800 mL
– 800 mL).
Each of the column fractions were assayed by a modified Aminoff TBA assay
Method. 100 μL of the fraction was incubated with 200 μL of NaIO4 (25mM in
0.125M H2SO4) for 10 minutes at room temperature.44 This step oxidized the
monosaccharide. Excess oxidizing reagent was reduced by addition of 400 μL of
NaAsO4 (2% wt/vol in 0.5 M HCl), and the reaction went to completion after the
solution moved from clear to brown/dark yellow before back to clear.44 After the
reaction was completed 2 mL of thiobarbituric acid (TBA) (0.36% wt/vol, pH 9) was
added and the reaction was heated at 100°C for 10 minutes.Error! Bookmark not defined.
DAH and DAHP containing fractions were combined and concentrated. The
buffer was removed via azeotropic distillation of 2-propanol.44 The DAHP and DAH
fractions were run down a Dowex 50 H+ column (20 mL) at 4°C. The eluent was
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concentrated to dryness and identified by 31P NMR 1H NMR.44 The DAHP was stored
at -20°C and used in the activity assay.

4.6 Conclusion on Synthesis
The synthesis of HqAla, the novel unAA, 2-(5-carboxylthienyl)alanine, and
DAHP were straightforward and obtained at good yields.

All products were

relatively stable and were used in the experiments described in Chapters 2 and 3.
The attempt at the synthesis of the diazirine threonine derivative however was not
achieved. It is likely that this small molecule is difficult to synthesize or the final
product is too unstable for use in a biological system. Though attempts were made
to synthesize this unAA, there were no successes.

4.7 Genetic Manipulation
(1) Plasmid Construction
Plasmid pBK-aroBwt was obtained by first amplifying the aroB gene from the
pQZ.116

plasmid

by

using

the

following

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’

and

primers

forward:

5’-

reverse

primer:

5’-

TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGCGCTGATTGACAATCGGCAATG-3’.
The PCR product was digested with EcoRI and HindIII as was installed by the
amplification. This was ligated into the pBK vector that was treated with the same
restriction enzymes, resulting in the plasmid pBK-aroBwt. The resulting plasmid
contains a kanamycin resistance marker, and the aroB gene was inserted behind the
constitutive glnS promoter (PglnS).
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Plasmid pBK-aroBE184A was obtained by modifying the Glu184 codon of the
aroB gene to CGC of pBK-aroBwt by site-directed mutagenesis using the following
primers, forward: 5’-CGTCGGGGCTGGCAGCGGTCATCAAATACGGCA-3’ and reverse:
3’-TGCCGTATTTGATGACCGCTGCCAGCCCCGACG-3’.
Plasmid pBK-aroBH264A was obtained by modifying the His 264 codon of the
aroB gene to CGC of pBK-aroBwt by site-direct mutagenesis using the following
primers, forward: 5’-GCTGAAATGGGGTATGGCAATTGGTTAGCGGGTGAAGCGGTCGC3’ and reverse: 5’-GCGACCGCTTCACCCGCTAACCAATTGCCATACCCCATTTCAGC-3’.
Plasmid pBK-aroBE184A/H264A by modifying the His264 codon of the aroB gene
to CGC of pBK-aroBE184A by site-direct mutagenesis using the following primers,
forward: 5’-GCTGAAATGGGGTATGGCAATTGGTTAGCGGGTGAAGCGGTCGC-3’ and
reverse: 5’-GCGACCGCTTCACCCGCTAACCAATTGCCATACCCCATTTCAGC-3’.
Plasmid pJF-aroBwt was obtained by digesting the pBK-aroBwt with HindIII
and EcoRI. The digested aroB gene was ligated with a pJF vector digested with the
same restriction enzymes. The resulting plasmid contains the ampicillin resistance
marker and the wild type aroB gene under the control of a hybrid tac promoter
(Ptac).
Plasmid pJF-aroBE184TAG/H264A was obtained by amplifying aroB gene of pBKaroBE184A/H264A

via

overlapping

PCR

with

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,

the

following

primers:

5’-

5’-TAGCGTCGGGGCTGGCATAGG

TCATCAAATACGG-3’, 5’-CCGTATTTGATGACCTATGCCAGCCCCGACGCTA-3’, and 5’TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGCGCTGATTGACAATCGGCAATG-3’.
This changed the Ala 184 codon to TAG and this PCR product was digested with
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HindIII and EcoRI. The digested aroB gene was ligated with a pJF vector digested
with the same restriction enzymes. The resulting plasmid contains the ampicillin
resistance marker and the variant aroBE184TAG/H264A gene under the control of a
hybrid tac promoter (Ptac).
Plasmid pJF-aroBE184A/H264TAG was obtained by amplifying aroB gene of pBKaroBE184A/H264A

via

overlapping

PCR

with

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,
TTATAGGGTGAAGCGGTC-3’,
CATTTCA-3’,

and

the

following

primers:

5’-

5’-TGAAATGGGGTATGGCAATTGG

5’-GACCGCTTCACCCTATAACCAATTGCCATACCC

5’-TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGCGCTGATT

GACAATCGGCAATG-3’. This changed the Ala264 codon to TAG and this PCR product
was digested with HindIII and EcoRI. The digested aroB gene was ligated with a pJF
vector digested with the same restriction enzymes. The resulting plasmid contains
the ampicillin resistance marker and the variant aroBE184A/H264TAG gene under the
control of a hybrid tac promoter (Ptac).
Plasmid pJF-aroBE184Y was obtained by amplifying aroB gene of pJF-aroBwt
via

overlapping

PCR

with

the

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,

following

primers:

5’-

5’-GCGTCGGGGCTGGCATATGTCAT

CAAATACGGCA-3’, 5’-TGCCGTATTTGATGACATATGCCAGCCCCGACGC-3’, and 5’TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGCGCTGATTGACAATCGGCAATG-3’.
This changed the Glu 184 codon to TAG and this PCR product was digested with
HindIII and EcoRI. The digested aroB gene was ligated with a pJF vector digested
with the same restriction enzymes. The resulting plasmid contains the ampicillin

87
resistance marker and the variant aroBE184Y gene under the control of a hybrid tac
promoter (Ptac).
Plasmid pJF-aroBH264Y was obtained by amplifying aroB gene of pJF-aroBwt
via

overlapping

PCR

with

the

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,

following

primers:

5’-

5’-ATGGGGTATGGCAATTGG

TTATATGGTGAAGCGG-3’, 5’-CCGCTTCACCATATAACCAATTGCCATACCCCAT-3’, and
5’-TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGCGCTGATTGACAATCGGCAATG-3’.
This changed the His 264 codon to TAG and this PCR product was digested with
HindIII and EcoRI. The digested aroB gene was ligated with a pJF vector digested
with the same restriction enzymes. The resulting plasmid contains the ampicillin
resistance marker and the variant aroBH264Y gene under the control of a hybrid tac
promoter (Ptac).
Plasmid pJF-aroBH251TAG was obtained by amplifying aroB gene of pJF-aroBwt
via

overlapping

PCR

with

the

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,
TGGTTAGGCCATTGAAGCTGAAAT-3’,
TGTGTCCCAGATTC-3’,

and

following

primers:

5’-

5’-GAATCTGGGACACACACCTT

5’-ATTTCAGCTTCAATGGCCTAACCAAAGG

5’-TGTCATAAGCTTTCAGTGGTGGTGGTGGTGGTGC

GCTGATTGACAATCGGCAATG-3’. This changed the His 251 codon to TAG and this
PCR product was digested with HindIII and EcoRI. The digested aroB gene was
ligated with a pJF vector digested with the same restriction enzymes. The resulting
plasmid contains the ampicillin resistance marker and the variant aroBH251TAG gene
under the control of a hybrid tac promoter (Ptac).
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Plasmid pJF-aroBH251TAG-pylT was obtained by amplifying the pyltRNA
sequence

from

pBK-mmPylT

with

the

following

ACCACCACTGAAAGCTTCCATGGTTCCACAGGGTAGCCAGCAG-3’,

primers:
and

5’5’-

TCCGCCAAAACAGCCAAGCTCTCGAGCAGAACATATCCATC-3’. This PCR product was
used with the pJF-aroBH251TAG plasmid digested with HindIII for SLIC cloning. The
pylT sequence was incorporated behind the aroBH251TAG gene, and changed the 3’
HindIII site to a NcoI site.
Plasmid pJF-aroBH264TAG-pylT was obtained by amplifying aroB gene of pJFaroBE184A/H264TAG

via

overlapping

PCR

with

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,

the

following

and

primers:

5’-

5’-GGAACCATGGAA

GCTTTCAGTGG-3’. This PCR product was digested with SacII and NcoI. The digested
aroB fragment was ligated with a pJF--aroBH251TAG-pylT vector digested with the
same restriction enzymes. The resulting plasmid contains the ampicillin resistance
marker and the variant aroBE184A/H264TAG gene under the control of a hybrid tac
promoter (Ptac) with a pylT sequence behind the aroB gene.
Plasmid pJF-aroBH251CAG-pylT was obtained by amplifying aroB gene of pJFaroBE184A/H264TAG

via

overlapping

PCR

with

GTCGAATTCATGGAGAGGATTGTCGTTACTC-3’,
TGGTCAGGCCATTGAAGCTGAAAT-3’,

the

following

primers:

5’-

5’-GAATCTGGGACACACACCTT

5’-ATTTCAGCTTCAATGGCCTGACCAAAGG

TGTGTCCCAGATTC-3’ and 5’-GGAACCATGGAA GCTTTCAGTGG-3’. This changed the
His 251 codon to Gln (CAG) and this PCR product was digested with SacII and NcoI.
The digested aroB fragment was ligated with a pJF--aroBH251CAG-pylT vector digested
with the same restriction enzymes. The resulting plasmid contains the ampicillin
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resistance marker and the variant aroBE184A/H264TAG gene under the control of a
hybrid tac promoter (Ptac) with a pylT sequence behind the aroB gene.
Plasmid pET-BrThaRSFull Length was obtained by amplifying out the BrThaRS
from

the

pBK-BrThaRS

plasmid

TTCATATGGATAAAAAACCATTAG-3’,

using
and

the

following

primers:

5’-

5’-AAGGATCCTTATAGATTGGTT

GAAATCCC-3’. This PCR product was digested with BamHI and NdeI and ligated into
the pET28a vector digested with the same enzymes. The resulting plasmid contains
the kanamycin resistance marker and the BrThaRSFull Length sequence under the
control of a T7 promoter.
Plasmid pET-BrThaRSTruncated was obtained by amplifying out the BrThaRS
from

the

pBK-BrThaRS

plasmid

using

the

following

primers:

5’-

CCCATATGGCTCCTGCTCCTTCACTTAC -3’, and 5’-AAGGATCCTTATAGATTGGTT
GAAATCCC-3’. This PCR product was digested with BamHI and NdeI and ligated into
the pET28a vector digested with the same enzymes. The resulting plasmid contains
the kanamycin resistance marker and the BrThaRSFull Length sequence under the
control of a T7 promoter.
Plasmid pBK-BrThaRSRandom mutagenesis library was obtained by amplifying out
the BrThaRS mutant from pBK-BrThaRS using the following primers and the
enzyme mutazyme DNA polymerase that makes small errors during amplification:
5’-GCGGCTTTGTTGAATAAATCGAAC-3’, and 5’-CAGACATCATGTAGGCCTG-3’. This
PCR product was digested with NdeI and PstI and ligated back into a new pBK vector
digested with the same enzymes. The resulting plasmid contains a kanamycin
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resistance marker, and the randomly mutated BrThaRS sequence was inserted
behind the constitutive glnS promoter (PglnS).

(2) Strain manipulation
Strains used particular to this work were AB2847 and JWΔaroB. Both strains
were received from the E. coli Genetic Stock Center at Yale University. The strains
specifics are as follows:

AB2847 from E. coli Genetic Stock Center
Chromosomal Makers: tsx-354, glnV42(AS), λ-, aroB351, malT354(λR)

JW3352-1 from E. coli Genetic Stock Center
Chromosomal

Markers:

Δ(araD-araB)567,

ΔlacZ4787(::rrnB-3),

λ-,

ΔaroB724::kan, rph-1, Δ(rhaD-rhaB)568, hsdR514

For use of the JW strain in the work described in this thesis the Kanamycin
marker (Kanr), that was placeholder to aroB724 gene, was removed by the following
method:
-

Competent cells of JW3351-1 were made by growing inoculated 5mL culture
overnight at 30°C until OD 0.4. Centrifuged down for 10 minutes at 4°C and
5000g. Re-suspended with cooled CCMB solution and centrifuged again for
10 minutes at 4°C and 5000g. Cells re-suspended in 200 μl of CCMB and
chilled overnight at -80°C.
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-

Transformed JW3352 with pCP20 and plated on Amp100, incubated overnight
at 30°C. 8 colonies were selected and plated onto pi plate (LB Amp100) and
grown at 30°C overnight.

-

1 colony selected from each of the pi and re-streaked on pi plate (LB) and
grown overnight at 42°C.

-

2 colonies from each pi taken for replicate on (LB), (LB Amp100), (LB Kan50)
and grown overnight at 37°C.

-

4a and 4b on initial 16 colonies did not grow on (LB Amp 100) so these
colonies taken and grown and prepared for a competent cell line for the
experiment

The genotype of the aroB gene was confirmed using the following primers for
AB2847:
Forward Primer: 5’-GTATGGAGAGATTGCCGACGTGAC-3’
Reverse primer: 5’-GGTTTCAGCTCGTCTTCTGGTTTG-3’

(3) Preparation of cultures for growth tests
5 mL culture of LB (Amp100/Cm34) inoculated with pJF-aroB mutant in JWΔaroB
strain and incubated overnight at 37C. 500ul of cells were taken and pelleted down.
Re-suspended in 500 μL of M9 minimal media without aromatic amino acids and
vitamins. Pelleted down and re-suspended with 500 μL of M9 minimal media
without aromatic amino acids and vitamins. 100 μl of washed cells used to inoculate
following cultures:
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(1) M9 minimal media with aromatic amino acids and vitamins+ 0.25 mM
IPTG
(2) M9 minimal media without aromatic amino acids and vitamins
(3) M9 minimal media without aromatic amino acids and vitamins + 0.25 mM
IPTG
(4) M9 minimal media without aromatic amino acids and vitamins + 0.25 mM
IPTG + 2mM unAA
(5) M9 minimal media without aromatic amino acids and vitamins + 0.25 mM
IPTG + 2mM unAA + 1x Trace elements
30 μL of each culture was taken for OD reading. Repeated at each time point – in
case of cultures with unAA, these were pelleted down and re-suspended in M9
minimal media without aromatic amino acids and vitamins.
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